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Amplification, deletion, and loss of heterozygosity of genomic DNA are hallmarks of cancer. In recent years a variety of
studies have emerged measuring total chromosomal copy number at increasingly high resolution. Similarly, loss-of-
heterozygosity events have been finely mapped using high-throughput genotyping technologies. We have developed
a probe-level allele-specific quantitation procedure that extracts both copy number and allelotype information from
single nucleotide polymorphism (SNP) array data to arrive at allele-specific copy number across the genome. Our
approach applies an expectation-maximization algorithm to a model derived from a novel classification of SNP array
probes. This method is the first to our knowledge that is able to (a) determine the generalized genotype of aberrant
samples at each SNP site (e.g., CCCCT at an amplified site), and (b) infer the copy number of each parental chromosome
across the genome. With this method, we are able to determine not just where amplifications and deletions occur, but
also the haplotype of the region being amplified or deleted. The merit of our model and general approach is
demonstrated by very precise genotyping of normal samples, and our allele-specific copy number inferences are
validated using PCR experiments. Applying our method to a collection of lung cancer samples, we are able to conclude
that amplification is essentially monoallelic, as would be expected under the mechanisms currently believed
responsible for gene amplification. This suggests that a specific parental chromosome may be targeted for
amplification, whether because of germ line or somatic variation. An R software package containing the methods
described in this paper is freely available at http://genome.dfci.harvard.edu/;tlaframb/PLASQ.
Citation: LaFramboise T, Weir BA, Zhao X, Beroukhim R, Li C, et al. (2005) Allele-specific amplification in cancer revealed by SNP array analysis. PLoS Comput Biol 1(6): e65.
Introduction
Genomic alterations are believed to be the major under-
lying cause of cancer [1–3]. These alterations include various
types of mutations, translocations, and copy number alter-
ations. The last category involves chromosomal regions with
either more than two copies (ampliﬁcations), one copy
(heterozygous deletions), or zero copies (homozygous dele-
tions) in the cell. Genes contained in ampliﬁed regions are
natural candidates for cancer-causing oncogenes [4], while
those in regions of deletion are potential tumor-suppressor
genes [5]. Thus, the localization of these alterations in cell
lines and tumor samples is a central aim of cancer research.
In recent years, a variety of array-based technologies have
been developed to identify and classify genomic alterations
[6–8]. Studies using these technologies typically analyze the
raw data to produce estimates of total copy number across
the genome [9–11]. However, these studies ignore the
individual contributions to copy number from each chromo-
some. Thus, for example, if a region containing a hetero-
zygous locus undergoes ampliﬁcation, the question of which
allele is being ampliﬁed generally remains unanswered. The
ampliﬁed allele is of interest because it may have been
selected for ampliﬁcation because of its oncogenic effect.
Data from array-based platforms have also been employed to
identify loss-of-heterozygosity (LOH) events [12,13]. In these
studies LOH is typically inferred to have occurred where
there is an allelic imbalance in a tumor sample at the same
site at which the matched normal sample is heterozygous. A
complicating issue (particularly in cancer) is that the
imbalance may be due to the ampliﬁcation of one of the
alleles rather than the deletion of the other, and thus LOH
may not in fact be present.
Copy number analysis and LOH detection can both be
improved by combining copy number measurement with
allelotype data. In this paper, we present a probe-level allele-
speciﬁc quantitation (PLASQ) procedure that infers allele-
speciﬁc copy numbers (ASCNs) from 100K single nucleotide
polymorphism (SNP) array [7] data. Our algorithm yields
highly accurate genotypes at the over 100,000 SNP sites. We
are also able to infer parent-speciﬁc copy numbers (PSCNs)
across the genome, making use of the fact that PSCN is locally
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numbers of each of the two parental chromosomes.) Our
results also allow the distinction to be made between true
LOH and (false) apparent LOH due to the ampliﬁcation of a
portion of only one of the chromosomes.
The PSCNs of 12 lung cancer samples that we initially
analyzed reveal almost exclusively monoallelic ampliﬁcation
of genomic DNA, a result that we subsequently conﬁrm in 89
other lung cell lines and tumors. Monoallelic ampliﬁcation
has previously been noted in the literature on the single gene
level [14–16], wherein mutant forms of known oncogenes are
ampliﬁed, while their wild-type counterparts are left unal-
tered. To our knowledge, this phenomenon has not pre-
viously been described on a genome-wide scale, though
proposed mechanisms of ampliﬁcation such as unequal sister
chromatid exchange [17] would suggest monoallelic ampliﬁ-
cation as the expected result.
In addition, our ASCNs identify the SNP haplotypes being
ampliﬁed. These haplotypes could conceivably serve as
markers for deleterious germ line mutations via linkage
disequilibrium. Indeed, the presence of monoallelic ampliﬁ-
cation makes such linkage studies statistically tractable (see
Discussion).
Results
Model Specification and Justification
The 100K SNP array set [7] is a pair of arrays, correspond-
ing to the HindIII and XbaI restriction enzymes, that together
are able to interrogate over 100,000 human SNPs. Herein, we
shall refer to the pair simply as the 100K SNP array. Its
original intended use was to query normal human DNA at
speciﬁc SNP sites, using a probe set of 40 25-mer oligonu-
cleotide probes to interrogate each SNP. The aim is to
identify which of the two alleles—arbitrarily labeled allele A
and allele B—occurs in each chromosome at each SNP site.
(Note that a diploid normal genome is implicitly assumed,
though there are recent reports of copy number variation in
normal cells [18,19].) An individual can therefore be
genotyped at each SNP as either homozygous AA, homo-
zygous BB, or heterozygous AB.
The design of the array is such that each probe may be
classiﬁed as either a perfect match (PM; perfectly comple-
mentary to one of the target alleles), or a mismatch (MM;
identicaltoaperfectmatchprobeexceptthatthecenterbaseis
altered so as to be perfectly complementary to neither allele).
Further,probesmaybesubclassiﬁedaccordingtowhetherthey
arecomplementarytoalleleAoralleleB,yieldingfourtypesof
probes: PMA,M M A,P M B, and MMB. A third subclassiﬁcation is
relevant. A probe may either be centered precisely at the SNP
site, or may be offset by between one and four bases in either
direction. This results in eight types of probes:
PMc
A; MMc
A; PMc
B; MMc
B; PMo
A; MMo
A; PMo
B; and MMo
B. Here
the superscripts c and o denote ‘‘centered’’ and ‘‘offset,’’
respectively. Examples of each probe type and their base
mismatch properties for a hypothetical SNP are shown in
Figure 1. Our model relates a probe’s intensity to the number
of bases at which it mismatches each of the two allele targets
(see below). Note that the eight probe types collapse to ﬁve
types with respect to afﬁnity for each allele, so that each of the
40 probes in a probe set may be classiﬁed as
PMA; PMB; MMc; MMo
A; or MMo
B.
As a ﬁrst step, we invariant-set normalized [20] all arrays to
the same pair (one for the HindIII array and the other for the
XbaI array) of baseline arrays using the dChip software (http://
www.dchip.org). (Normalization is a standard ﬁrst step in the
analysis of microarray data, and is meant to eliminate
unwanted artifacts such as differences in overall array
brightness.) Our subsequent analyses are all based on a
model that speciﬁes probe intensity as a linear function of the
copy numbers of both alleles. The underpinnings of this
model are justiﬁed by empirical evidence that the signal from
oligonucleotide probes is proportional to target quantity up
until the point at which the probe becomes saturated [21].
Figure 1. A Hypothetical Example of the Eight Probe Types in the 100K
SNP Array [7]
Each probe is a 25-mer designed to be at least partially complementary
to a portion of the target fragment. In this diagram, the target contains
an A (A allele)/C (B allele) SNP, as shown in brackets. The middle (13th)
base of each probe is underlined, and the base corresponding to the SNP
site is indicated in bold. The offset probes here are offset by two bases.
From the sequences, one can count the number of bases that each
probe mismatches each target allele (right columns).
DOI: 10.1371/journal.pcbi.0010065.g001
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Synopsis
Human cancer is driven by the acquisition of genomic alterations.
These alterations include amplifications and deletions of portions of
one or both chromosomes in the cell. The localization of such copy
number changes is an important pursuit in cancer genomics
research because amplifications frequently harbor cancer-causing
oncogenes, while deleted regions often contain tumor-suppressor
genes. In this paper the authors present an expectation-max-
imization-based procedure that, when applied to data from single
nucleotide polymorphism arrays, estimates not only total copy
number at high resolution across the genome, but also the
contribution of each parental chromosome to copy number.
Applying this approach to data from over 100 lung cancer samples
the authors find that, in essentially all cases, amplification is
monoallelic. That is, only one of the two parental chromosomes
contributes to the copy number elevation in each amplified region.
This phenomenon makes possible the identification of haplotypes,
or patterns of single nucleotide polymorphism alleles, that may
serve as markers for the tumor-inducing genetic variants being
targeted.
Allele- and Parent-Specific Copy NumberA similar linear model has been well established for use
with expression array data [22]. In our model, however, the
proportionality parameters depend upon the numbers of
bases at which the probe mismatches each target allele.
Therefore, we specify the model for (normalized) probe
intensity Yk of the kth probe in a ﬁxed SNP’s probe set as
Yk ¼ a þ bAkCA þ bBkCB þ e ð1Þ
Here CA and CB are the copy numbers of the A and B
alleles, respectively, in the sample being interrogated, and Ak
and Bk denote the number of bases (either 0, 1, or 2) at which
the kth probe is not perfectly complementary to the A and B
targets, respectively. For example, it follows from Figure 1
that the model speciﬁes a PMA probe’s intensity as aþb0CAþ
b1CB þ e. The ﬁrst term, a, represents background signal,
which can arise from optical noise and nonspeciﬁc binding
[23], and the error e is a normally distributed mean-zero term
meant to capture additional sources of variation. Hence the
model parameters are a, b0, b1, and b2. These parameters are
allowed to be different for forward and reverse strands, and
to vary from SNP to SNP, but are assumed to be constant
within same-strand portions of probe sets and across differ-
ent samples in a study. They effectively encode the binding
afﬁnities between the probes and targets for each SNP.
Finally, our experience indicates that the two-base mismatch
signal is essentially indistinguishable from background noise,
and hence we set b2 ¼ 0.
From model equation 1 and Figure 1, it directly follows
that the background-subtracted mean intensities in a normal
sample should depend upon the genotype at the SNP in
normal samples according to the inset table in Figure 2. We
ﬁt the model to data from nine samples—NA6985, NA6991,
NA6993, NA12707, NA12716, NA12717, NA12801, NA12812,
and NA12813—that were gathered as part of the Interna-
tional HapMap Project (http://www.hapmap.org). An example
of the model ﬁt is illustrated for a speciﬁc SNP (rs 2273762) in
Figure 2. We estimated values ^ a, ^ b, and ^ b1 for the parameters
a, b0, and b1, along with genotyping calls for each sample
using an expectation-maximization algorithm [24] (see
Materials and Methods). In the ﬁgure, it can be seen that
each probe classiﬁcation’s mean intensity agrees closely with
that assumed by the model (inset table). This is an indication
that the model provides a reasonably accurate description of
the data.
Genotyping of Normal Samples
We applied our method to the nine samples (see above)
that were independently genotyped by centers in the
International HapMap Project consortium. Nine different
centers were involved in the genotyping of these samples.
They employed a variety of platforms, including mass
spectroscopy, enzymatic reactions, hybridization, and poly-
merase chain reaction (PCR)–based techniques. There are
approximately 22,000 SNPs that are represented in both the
100K SNP array and the HapMap effort. In the nine samples
we studied, a total of 1,198 SNPs were genotyped by two or
more different HapMap centers, resulting in 10,782 sample
SNP calls. The concordant calls among these multiply
genotyped sample SNPs may be treated as being very close
to a ‘‘gold standard’’ result, and we used these as a benchmark
Figure 2. Average Intensities for Each Probe Type by Sample at a Single SNP (rs 2273762)
The inset table gives the average background-subtracted intensities that would be predicted by our model. The actual background-subtracted mean
intensity values (bar graph) in each sample closely agree with what is predicted (inset table).
DOI: 10.1371/journal.pcbi.0010065.g002
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Allele- and Parent-Specific Copy Numberagainst which to evaluate the accuracy of our calls. Table 1
summarizes the comparison. The HapMap results have a
98.7% call rate. Among those called, the concordance rate
between centers exceeds 99%. Our genotyping algorithm
performs quite well, achieving a call rate of 99.27%, and
disagreeing with the consensus HapMap genotyping for less
than 1% of the calls. The results point to a very high rate of
accuracy for our method, and speak well to the suitability of
the model.
A feature of Table 1 that bears further comment is the fact
that 16 sample SNPs were called AA by our algorithm and BB
by the HapMap consortium. All 16 of these discrepancies
occur in either of two SNPs, rs 1323113 or rs 2284867. Close
inspection of the raw intensities of the 40 probes at each of
these SNPs (data not shown) reveals a strong AA signal for the
samples in question. A likely explanation is that the A and B
labels were inadvertently switched for these two SNPs when
Affymetrix matched its notation to the HapMap effort’s
alleles.
ASCNs and PSCNs in Cancer DNA Samples
The distinction between ASCN and PSCN may be best
understood by considering a hypothetical example of four
consecutive SNPs in a genomic region with a total copy
number of ﬁve. Suppose that the allele A copy numbers for
the SNPs are four, zero, ﬁve, and one, respectively, leaving
allele B copy numbers as one, ﬁve, zero, and four. These are
what we mean by ASCNs. Taken individually, the ASCNs for
the second and third SNPs are noninformative with regard to
PSCN, as both the maternal and paternal chromosomes have
the same alleles. However, the ﬁrst and fourth SNPs both
indicate that one of the parental chromosomes was ampliﬁed
to a copy number of four, while the other is unaltered. Thus,
we infer PSCNs of four and one for the entire genomic region
containing the four SNPs. The ASCN at a SNP site may be
viewed as a generalized genotype of the sample.
We initially tested our PLASQ algorithm on a set of 12 lung
cancer samples for which we have recently reported total
copy number analysis [25], after calibrating the model on 12
normal samples. The cancer samples included one small cell
primary tumor, two non-small cell primary tumors, and nine
cell lines. Please refer to [25] and the Materials and Methods
for additional details. All inferred homozygous deletions are
provided in Table 2, while all inferred ampliﬁcations with
total copy number of at least ﬁve are in Table 3. The genome-
wide view of inferred PSCN is shown for the H2122 and
HCC95 cell lines in Figure 3. The absence of minor
chromosome copy numbers (red bars) at high levels on the
plot shows that the ampliﬁcations are essentially monoallelic.
All amplicons with total inferred copy number of at least
ﬁve, throughout all 12 samples, are shown in Figure 4. The
most striking feature of this graph is the fact that the vast
majority of ampliﬁcations exclusively involve only one of the
two parental chromosomes. That is, ampliﬁcation here is
monoallelic. Also clear from the ﬁgure is the distinction
between true LOH (bars with no red portion) and false LOH
(bars partly red). We repeated our analysis on 89 other
samples (data not shown), on which we similarly obtained the
result that amplicons are almost entirely composed of only
one of the two parental chromosomes.
To experimentally validate our PLASQ approach using an
independent method, we applied allele-speciﬁc real-time
PCR. ASCN analysis required changes to the standard copy
number analysis by real-time PCR. Standard conditions using
Taq polymerase caused the ampliﬁcation of the target allele,
as well as delayed ampliﬁcation from the other SNP allele.
The Stoffel fragment of Taq polymerase, which lacks that
enzyme’s normal 59 to 39 exonuclease activity, increases the
speciﬁcity of the enzyme for the correct target [26,27]. This
consequently increases the ampliﬁcation delay enough to
distinguish the two alleles and calculate accurate copy
numbers.
In [25], we used standard real-time PCR to verify the total
copy number for ‘‘recurrent’’ ampliﬁcations and deletions.
We deﬁned an event to be recurrent if it occurred in at least
two samples, contained at least four SNPs, and was at least 5
kb in length. The comparison of our PLASQ analysis to both
allele-speciﬁc and standard real-time PCR is given in Tables 4
and 5 for these recurrent events that occur in our initial 12
samples. PLASQ largely agrees with the PCR measurements
for homozygous deletions (Table 4). For ampliﬁcations (Table
5), there is strong concordance between our estimates and the
allele-speciﬁc PCR results. The rounded minor allele esti-
mates differ by at most one copy in all but one case. With
regard to major allele copy number inferences in Table 5, our
estimates tend to be somewhat low, though they are always at
elevated levels where the PCR results are. These discrepancies
are likely the result of saturation effects that are well known
in oligonucleotide arrays [28]. There is only one case where
the total PCR estimate from [25] is lower than the PLASQ
total. Here the allele-speciﬁc PCR results are in closer
Table 1. Concordance between Our Model’s Calls and Those Made by More Than One Center in the International HapMap Project
Effort
HapMap Call Model AA Model AB Model BB Model No Call Totals
HapMap AA 3,774 (35.00%) 2 (0.02%) 0 (0%) 18 (0.17%) 3,794 (35.19%)
HapMap AB 40 (0.37%) 3,070 (28.47%) 37 (0.34%) 36 (0.33%) 3,183 (29.52%)
HapMap BB 16
a (0.15%) 8 (0.07%) 3,578 (33.18%) 24 (0.22%) 3,626 (33.63%)
HapMap no call 46 (0.43%) 46 (0.43%) 48 (0.45%) 1 (0.01%) 141 (1.3%)
HapMap discordant 4 (0.04%) 26 (0.24%) 8 (0.07%) 0 (0%) 38 (0.35%)
Totals 3,880 (35.99%) 3,152 (29.23%) 3,671 (34.05%) 79 (0.73%) 10,782 (100%)
HapMap’s calls are considered discordant if any two centers, neither producing a no call for the SNP, call it differently. If all but one center produce a no call, the SNP is placed in the table’s ‘‘HapMap no call’’ category.
aLikely the result of mislabeled A and B alleles (see text).
DOI: 10.1371/journal.pcbi.0010065.t001
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Allele- and Parent-Specific Copy Numberagreement with our inferred ASCN, indicating that this is an
experimental error in the standard real-time PCR.
One type of discrepancy in Table 5 stands out. In two cases,
PLASQ infers an ASCN of one, whereas the experimentally
determined copy number was essentially zero. One possible
explanation is that our inference is correct and the low PCR
estimates are attributable to experimental errors such as
suboptimal primer sequences. On the other hand, our ASCN
calls are somewhat vulnerable to the inherent noise in
hybridization-based intensity measurements. At the single
SNP level, deviations of one copy number in either direction
may be difﬁcult to detect because of this noise, resulting in
slightly inaccurate ASCN calls. However, these inaccuracies
are ameliorated in PSCN calls since we may ‘‘borrow
strength’’ from neighboring SNPs’ raw ASCNs because of
the locally constant property of PSCN. Thus, for example, the
LOH calls for regions will be very precise even when
individual ASCN calls are slightly erroneous.
It is important to note that in all cases, the property of
interest—the presence or absence of ampliﬁcation or
deletion in each chromosome—is clearly detectable with
our method, as all approaches agree in this regard. Finally, in
order to assess the accuracy of our determination of
amplicon and deletion boundaries, we compared the results
that were determined in [25] using an algorithm implemented
in the dChipSNP computational platform [9] to our results.
The comparison is shown in Table 6 for the events in Tables
4 and 5. In most cases, our estimated alteration boundaries
correspond exactly to those inferred by dChipSNP. Events for
which the two approaches differ in their inferences could be
due to procedural differences such as varying copy number
thresholds used to determine whether or not a gain should be
called an ampliﬁcation.
Amplification of EGFR Mutant
In order to determine whether ampliﬁcation could target,
in a monoallelic fashion, an activating mutation in one of our
samples, we examined sequence data for the EGFR gene. It
was shown in [25] that the HCC827 cell line harbors the E746
A750del deletion mutant. This is a known activating mutation
[29,30], and our result in Table 5 predicts ASCNs of 11 and
two at this locus. It was interesting, therefore, to determine
whether the greatly ampliﬁed chromosome is the one
harboring the mutation. To answer this question, we
performed quantitative PCR experiments that are able to
differentiate the wild-type copies from the mutant copies (see
Materials and Methods). The wild-type allele was found to be
unampliﬁed (PCR estimate 0.80), while the total PCR copy
number was 39.78. Thus, our method uncovered a targeted
ampliﬁcation of an activating mutant allele over its wild-type
counterpart.
Discussion
Many genomic events of interest are easily placed in the
context of ASCN and PSCN. LOH at a SNP site occurs where
one of the PSCNs is zero. Monoallelic ampliﬁcation occurs at
loci where one parental chromosome has a copy number less
than two and the other has a copy number greater than one.
We have demonstrated that these events, among others, may
be identiﬁed though ASCN and PSCN from 100K SNP array
data. Examining array data from over 100 lung cancer
samples, we have found that ampliﬁcations are overwhelm-
ingly monoallelic. Current understanding of the mechanisms
behind ampliﬁcation in tumorigenesis would suggest this as
an expected result. For example, Herrick et al. [17] describe
mechanisms that would all lead to monoallelic ampliﬁcation
in genes. To our knowledge, however, this phenomenon has
not been demonstrated on a genome-wide scale in the
literature.
Previous studies have demonstrated monoallelic ampliﬁca-
tion at speciﬁc genes. Hosokawa and Arnold [14] found two
tumor cell lines in which a mutant allele of cyclin D1 is
ampliﬁed but the wild-type copy is not. Zhuang et al. [16]
uncovered a similar trend in 16 renal carcinoma tumors
heterozygous for a MET mutation, and a study of 26 mouse
skin tumors found 16 with a mutant HRAS homolog allele
ampliﬁed but none with the wild-type allele ampliﬁed [15].
Using our procedure, we have uncovered (and validated) an
EGFR example in one of our samples. These cases highlight
the targeting of one genetic variant for ampliﬁcation over
another at a heterozygous site, presumably in order to give
the cell growth advantage. However, further studies involving
a larger set of tumors are necessary to uncover multiple
instances of the transforming variant being the ampliﬁcation
target. A large number of such cases would provide
compelling evidence for the biological signiﬁcance of allele-
speciﬁc ampliﬁcation of genes. In some studies these
monoallelic ampliﬁcations may be erroneously called LOH
Table 2. All PLASQ-Inferred Homozygous Deletions, across 12
Lung Cancer Samples
Chromosome Start (Mb) End (Mb) Sample
2 18.36 22.20 H2882
2 31.35 31.47 HCC1359
2 51.32 51.59 S0177
2 141.71 142.45 H2122
2 141.94 142.20 H157
2 141.94 142.20 H2126
2 142.21 142.78 HCC95
3 60.29 60.54 HCC95
3 76.73 77.24 HCC95
3 152.82 152.95 H2882
4 92.20 92.57 H2126
4 182.83 183.21 H2087
8 3.86 4.43 HCC95
8 9.45 10.15 HCC1171
8 137.65 137.86 H2122
9 8.61 9.12 S0177
9 9.41 9.61 HCC1171
9 20.90 22.94 H2126
9 21.20 22.19 HCC1359
9 21.58 25.10 HCC1171
9 21.70 22.94 H2882
9 21.84 22.09 H2122
9 21.84 26.83 HCC95
9 23.15 23.39 H2882
9 24.33 24.72 H157
9 38.43 38.45 H2087
10 11.23 11.80 H2126
10 34.63 34.79 H157
13 54.57 55.11 S0177
18 64.00 64.08 S0515
X 6.43 7.24 H157
DOI: 10.1371/journal.pcbi.0010065.t002
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Allele- and Parent-Specific Copy Numberbecause of the allelic imbalance. Our approach was able to
determine that, in most cases, the minor allele is not in fact
deleted, and thus LOH has not occurred.
ASCN information may be used to identify SNP haplotypes
in cancer cell amplicons. This haplotype structure determi-
nation has important applications for uncovering candidate
oncogenes and tumor suppressor genes. The applications
may be understood in the context of a recent study [31] that
characterizes the genome as consisting of haplotype blocks—
regions with few distinct haplotypes commonly observed in
human populations—separated by recombination ‘‘hot-
spots.’’ Indeed, consider an inherited variant that predisposes
a cell toward tumor growth and is selected for ampliﬁcation.
Many SNP sites located in the same haplotype block would be
ampliﬁed along with the variant. One may determine the
haplotype of the amplicon via ASCN. The SNP haplotype in
the same block as the gene, therefore, may serve as a marker
for the variant through genetic association studies [32]. We
point out that, were it not for monoallelic ampliﬁcation, this
endeavor would be far more difﬁcult, for if both parental
chromosomes were ampliﬁed then both haplotypes would be
candidate markers for the deleterious variant. Statistically,
the power to detect association would be signiﬁcantly
compromised.
Our method produces, in addition, highly accurate
genotype calls in normal cells. Analyzing sample SNPs that
were genotyped by at least two independent groups, we had
over 99% agreement with their concordant calls. Given the
strength of our results, we are now working to apply the
model to data from oligonucleotide resequencing arrays [33].
Note that our procedure is does not take into account all
types of genomic alterations. For example, it would be
somewhat confounded by a translocation event. A trans-
location would induce a loss of the ‘‘local constancy’’
property of total copy number. Similarly, point mutations
are not detectable with our approach, and in fact could
adversely affect copy number measurements if they were to
occur near 100K SNP sites. Still, we feel that these limitations
do not severely impact the applicability of the method.
The structure of our model suggests a very useful
extension. A common problem in analyzing the genomic
content of tumor cells is that of stromal contamination—the
presence of normal cells in the sample. Stromal contami-
nation makes accurate copy number determination difﬁcult
because the quantity measured is actually a weighted average
of the normal and cancer cell copy numbers. Mathematically,
the sample’s ASCNs at a ﬁxed SNP site may be expressed as
CA ¼ pSCAS þð 1   pSÞCAT
CB ¼ pSCBS þð 1   pSÞCBT; ð2Þ
Table 3. All PLASQ-Inferred Amplifications of Total Copy
Number of at Least Five, across 12 Lung Cancer Samples
Chromosome Start (Mb) End (Mb) Sample
1 147.13 148.83 HCC1171
1 147.16 151.89 H2126
1 150.42 158.73 HCC1171
1 185.41 186.11 H2087
1 188.01 190.38 HCC95
1 229.90 230.04 HCC95
2 125.13 125.25 S0465
3 4.92 5.24 H2882
3 75.99 76.09 H2882
3 169.63 170.89 S0465
3 173.28 174.45 HCC95
3 175.00 175.09 S0465
3 176.92 184.52 S0465
3 177.73 178.26 HCC95
3 181.47 187.98 HCC95
3 182.50 184.47 S0515
3 190.20 198.54 HCC95
6 11.60 11.96 HCC827
6 55.26 55.55 H157
6 64.08 64.29 H157
7 53.16 57.39 HCC827
7 85.94 86.94 H2126
7 133.08 133.26 H2126
7 151.29 151.93 HCC827
8 32.09 33.99 HCC95
8 38.50 40.33 H2882
8 43.13 47.26 HCC95
8 61.86 62.58 S0177
8 63.86 64.36 H2882
8 66.67 68.49 HCC827
8 70.57 71.29 HCC827
8 74.15 76.27 HCC827
8 80.79 82.81 HCC827
8 82.91 83.00 H2126
8 102.74 104.22 HCC827
8 124.15 124.52 HCC827
8 124.40 130.51 H2087
8 127.46 128.89 HCC827
8 127.90 128.07 H2122
8 129.43 129.61 H2122
8 129.80 131.20 H2126
8 129.98 133.65 HCC827
8 134.42 135.88 HCC827
9 27.14 27.21 S0515
10 25.92 27.47 H2087
10 33.74 35.67 H2087
10 59.08 59.25 H2087
10 82.18 83.57 HCC1359
10 86.63 87.16 HCC1359
11 34.11 39.15 HCC95
11 48.21 51.30 HCC95
12 14.12 15.24 HCC1359
12 20.76 20.91 HCC1359
12 32.17 33.02 S0515
12 32.69 34.29 H2087
12 50.90 52.16 H2087
12 56.26 57.28 H2087
12 59.44 59.78 H2087
12 63.22 63.61 HCC827
14 72.38 72.60 H2122
14 72.38 72.63 HCC827
17 22.27 25.88 HCC95
17 73.25 74.30 HCC1359
18 0.15 0.87 HCC95
19 43.01 45.00 S0515
19 45.80 49.70 H2882
21 15.48 18.46 HCC827
22 19.45 20.75 HCC1359
Table 3. Continued
Chromosome Start (Mb) End (Mb) Sample
22 22.35 23.48 HCC1359
22 48.32 2.33 HCC95
X 79.00 79.50 H2087
DOI: 10.1371/journal.pcbi.0010065.t003
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Allele- and Parent-Specific Copy Numberwhere pS is the (unknown) proportion of stroma, CAS and CBS
are the ASCNs of the stromal cells, and CAT and CBT are the
(unknown) ASCNs in the tumor. We may treat CAS and CBS as
known, since a matched normal sample may be genotyped at
the SNP. Thus, replacing CA and CB in our model with the
expressions in equation 2 above gives each probe’s intensity
as a function of true cancer cell ASCNs and proportion of
stromal content. Although beyond the scope of this paper,
this is an intriguing bioinformatic approach to a pervasive
experimental problem.
In summary, we have presented a procedure, termed
PLASQ, that is not only able to localize copy number
alterations in cancer cells, but can also identify each
chromosome’s contribution to these alterations as well as
the SNP haplotypes in each event. Our approach has been
validated using a variety of independent experimental
techniques. We have also described several applications and
extensions of our methods, and we have demonstrated that
chromosomal ampliﬁcations in human lung cancer are
monoallelic. Finally, it has come to our attention that, while
this work was under review, a pair of papers [34,35]
describing methods to infer PSCN from 100K SNP array
data was published. The approaches differ from ours, and
appear to require matched normal samples.
An R [36] package, downloadable at http://genome.dfci.
harvard.edu/;tlaframb/PLASQ, contains procedures and
data described in this work.
Materials and Methods
The PLASQ procedure for genotyping normal and aberrant
samples (thereby obtaining ASCN and PSCN), beginning with the
SNP array .cel ﬁles, is outlined in Figure 5. Details of each step are
given below and in the Results.
DNA samples. We obtained the Affymetrix .cel ﬁles from all lung
cancer tumors and cell lines analyzed in [25]. In our analysis, we used
the same raw probe-level data that were generated from the
experiments in that study. For initial analysis, we selected the cell
lines H157, H2087, H2122, H2126, H2882, HCC95, HCC827,
HCC1359, and HCC1171, as well as tumors S0177T, S0465T, and
S0515T. These 12 samples were chosen because each was found [25] to
harbor at least two of the copy number alterations that were
considered recurrent. We subsequently applied our approach to the
remaining 89 tumors and cell lines in that study. Additionally, the 12
normal samples from that paper were employed in the study. Details
about the preparation, hybridization, and image acquisition for all
samples may be found in [25], and all .cel ﬁles are available at http://
research2.dfci.harvard.edu/dfci/snp/. We obtained the HapMap sam-
ples’ .cel ﬁles from the Affymetrix Web site (http://www.affymetrix.
com).
Normal sample genotyping. In this case, for each sample the value
of CA at a SNP is either zero, one, or two. The value of CB is
completely determined by CA,a sCA þ CB ¼ 2. Thus, we may think of
each sample SNP as being in one of three states, corresponding to the
AA, AB, and BB genotypes. These states are not known a priori, and
neither are the values of a, b0, and b1. We employ an expectation-
maximization algorithm [24] at each SNP to infer the genotypes and
estimate the parameters. Brieﬂy, we ﬁrst initialize the probabilities of
the three genotypes of each sample using a crude t-test approach.
Based on these initial ‘‘guesses,’’ we apply ordinary least squares [37]
to our model, ﬁnding the maximum likelihood estimates of the
parameters a, b0, and b1 (the M step). Next, based upon these
estimates, we re-infer the genotype probabilities of each sample using
the expected values of the indicator variables for each of the three
Figure 3. A Depiction of PSCN across the Genome for the Cell Lines H2122 and HCC95
In both graphs green indicates the higher copy number parental chromosome, and red indicates the lower copy number parental chromosome. The
total height of each red/green bar indicates the total copy number at the corresponding SNP. Black bars represent homozygous deletions, where total
copy number is zero.
DOI: 10.1371/journal.pcbi.0010065.g003
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Allele- and Parent-Specific Copy Numberpossible genotypes (the E step). These two steps—maximization and
expectation—are iterated until the approximated values of all
unknowns converge. The result of this procedure is an estimated
probability of each genotype along with parameter estimates. The
algorithm’s call at each sample SNP is the genotype with the
maximum ﬁnal estimated probability, unless the maximum falls
under a user-deﬁned threshold (the default is 99%), in which case a
‘‘No Call’’ is given. We subsequently use the ﬁnal parameter estimates
^ a, ^ b, and ^ b1 of a, b0, and b1, respectively, in the application of the
model to data from cancer cells (see below).
Figure 4. PSCNs for All Discovered Amplicons with PLASQ-Inferred Total Copy Numbers of at Least Five
The height of each bar indicates the total copy number for that amplicon. The copy numbers for the parental chromosomes are represented by the red
and green portions of each bar. LOH occurs, as indicated, where there is no red portion.
DOI: 10.1371/journal.pcbi.0010065.g004
Table 4. Comparison of Inferred ASCNs with PCR Results for Deletions
Chromosome Position
(Mb)
Sample PLASQ Allele
A Copy Number
PLASQ Allele
B Copy Number
Real-Time PCR
Copy Number
a
Candidate
Genes
2 142.07 H2126 0 0 0.00 LRP1B
2 142.08 H2122 0 0 0.01
2 142.10 H157 0 0 0.06
2 142.29 HCC95 0 0 0.00
3 60.54 HCC95 0 0 0.00 FHIT
3 152.89 H2882 0 0 0.00 AADAC, SUCNR1
3 152.89 S0177T
b 1 1 0.02
9 8.87 S0177T 0 0 0.01 PTPRD
9 9.51 HCC1171 0 0 0.08
9 21.70 HCC1359 0 0 0.00 CDKN2A
9 21.92 H2126 0 0 0.00
9 22.02 H2122 0 0 0.01
9 22.55 H2882 0 0 0.00
9 23.34 HCC1171 0 0 0.00
9 24.34 HCC95 0 0 0.00
9 24.52 H157 0 0 0.03
Candidate tumor suppressor genes in each deleted region are given in the last column.
aFrom [25].
bDeletion detected in raw ASCN, but omitted in ASCN because span is only three SNPs (see Materials and Methods).
DOI: 10.1371/journal.pcbi.0010065.t004
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copy numbers of the A and B alleles are no longer constrained to sum
to two at each SNP. After calibrating the model on normal samples as
described above, we replace the parameters a, b0, and b1 in our model
with their estimates at each SNP. We directly apply least squares
estimation to ﬁnd raw inferences (‘‘raw’’ because we do not yet
exploit local constancy of total copy number) of the A and B copy
numbers at each SNP. These rough measures are referred to as the
raw ASCNs. While the ASCNs are not locally constant in a sample,
their pairwise sums CAþCB are. We therefore input the pairwise sums
of the raw ASCNs at each SNP into the circular binary segmentation
algorithm [38] to infer total copy number. This smoothing algorithm
exploits the fact that chromosomal alterations typically occur in
segments containing several SNPs. Brieﬂy, circular binary segmenta-
tion searches for locally constant sections by recursively splitting
chromosomes into candidate subsegments and computing a max-
imum t-statistic that reﬂects differences in mean total raw copy
number between subsegments. The reference distribution for this
statistic, estimated by permutation, is used to decide whether or not
to permanently split at each stage. The result is a segmentation of
each chromosome in a sample, where the total copy number is
deemed constant within each segment. Our raw total copy number of
a segment is the mean of the pairwise sums of the raw ASCNs of all
SNPs in the segment.
PSCNs and ASCNs. The circular binary segmentation algorithm
divides each sample’s genome into segments, each assumed to have
the same total copy number. Consider a segment with n SNPs and a
raw total copy number Traw. We infer PSCN for the segment as
follows. If n , 4, we consider Traw to be too noisy due to the small
number of observations, and infer PSCNs (1, 1). For n   4, if Traw  
Table 5. Comparison of Inferred ASCNs with PCR Results for Amplifications
SNP ID
(rs)
Chromosome Position
(Mb)
Sample PLASQ Allele
A Copy Number
PLASQ Allele
B Copy Number
PCR A
Copy Number
PCR B
Copy Number
PCR Total
Copy Number
a
Candidate
Genes
4859257 3 183.98 S0465T 5 1 25.18 1.68 10.29 PIK3CA
2049284 3 183.49 S0515T 1 10 2.42 38.37 3.90
1569265 7 54.61 HCC827 11 2 135.92 1.97 41.66 EGFR
2804228 8 128.04 H2122 6 1 58.46 3.39 14.5 MYC
9283954 8 128.33 HCC827 1 6 0.06 7.58 8.63
2392827 8 128.91 H2087 2 6 1.23 6.03 15.99
10506101 12 32.60 S0515T 0 8 0.06 7.12 10.75 PKP2
1486883 12 33.80 H2087 8 1 17.32 0.03 11.43
611421 12 57.20 H2087 8 1 4.86 0.17 23.4 CDK4
448041 22 19.77 HCC1359 1 9 1.03 8.36 8.05 CRKL
Candidate oncogenes in each amplicon are given in the last column.
aFrom [25].
DOI: 10.1371/journal.pcbi.0010065.t005
Table 6. Comparison of PLASQ-Inferred Lesion Boundaries with Those from [25]
Alteration
Type
Chromosome Sample PLASQ-Determined
Start (Mb)
dChipSNP-Determined
Start (Mb)
PLASQ-Determined
End (Mb)
dChipSNP-Determined
End (Mb)
Deletion 2 H2122 141.71 141.71 142.45 142.45
Deletion 2 H2126 141.94 141.94 142.20 142.20
Deletion 2 H157 141.94 142.00 142.20 142.20
Deletion 2 HCC95 142.21 141.79 142.57 142.78
Deletion 3 HCC95 60.29 60.29 60.52 60.78
Deletion 3 S0177T NA
a 152.82 NA
a 152.95
Deletion 3 H2882 152.83 152.82 152.87 152.95
Deletion 3 S0465T 176.92 174.86 184.52 184.52
Amplicon 3 S0515T 182.50 182.50 184.47 184.47
Amplicon 7 HCC827 53.16 53.16 57.39 61.49
Amplicon 8 HCC827 127.46 127.46 128.89 128.89
Amplicon 8 H2122 127.90 127.90 128.08 129.62
Amplicon 8 H2087 128.71 128.44 130.51 129.60
Deletion 9 S0177T 8.61 8.61 9.12 9.12
Deletion 9 HCC1171 9.41 9.41 9.61 9.61
Deletion 9 H2126 20.90 20.90 22.94 22.94
Deletion 9 HCC1359 21.20 21.20 22.19 22.19
Deletion 9 HCC1171 21.58 21.58 25.10 25.10
Deletion 9 H2882 21.70 21.70 22.94 22.94
Deletion 9 HCC95 21.84 21.84 26.83 26.83
Deletion 9 H2122 21.84 21.95 22.09 22.09
Deletion 9 H157 24.33 24.34 24.72 24.70
Amplicon 12 S0515T 32.17 32.17 33.02 33.02
Amplicon 12 H2087 32.69 32.69 34.29 36.59
Amplicon 12 H2087 56.26 56.26 57.28 57.37
Amplicon 22 HCC1359 19.45 19.45 20.75 20.75
aDeletion not detected using PLASQ approach (see Table 4).
DOI: 10.1371/journal.pcbi.0010065.t006
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(minor chromosome, major chromosome) ¼ (0, 0). If 0.35 , Traw  
1.35, we call a heterozygous deletion with PSCNs (0, 1). If Traw . 1.35,
our inferred total copy number T is simply Traw rounded to the
nearest integer (or to two if 1.35 , Traw   2.5), and we proceed as
follows.
Let A1, A2,..., An and B1, B2,..., Bn denote the raw ASCNs for the n
SNPs in a segment. We consider a SNP i to be homozygous if
minimum (Ai,B i)   0.5. We must ﬁrst consider the possibility that
one of the parental chromosomes is deleted while the other is
ampliﬁed, i.e., the SNP may be homozygous either because it was
homozygous in the normal cell, or because of LOH. Since the average
heterozygosity rate for SNPs on the array is 0.3 [39], the probability
of a randomly chosen SNP being homozygous is 0.7. Thus, we model
the number of homozygous SNPs in a segment without chromosomal
deletion as a binomial (n, 0.7) random variable X. The resulting
hypothesis test would reject the null hypothesis of no LOH at the a
level if
PðX   the actual number of homozygous SNPs in the regionÞ,a:
ð3Þ
Making a conservative Bonferroni correction for multiple testing on
the total number of segments s, we assume deletion of one
chromosome if the null hypothesis is rejected at the a ¼ 0.05/s level.
In this case, our inferred PSCNs are (0, T). Otherwise, note that (as
discussed in Results) homozygous SNP sites are noninformative with
regard to PSCN. Thus, we temporarily ignore those SNPs, leaving m
SNPs (m   n) whose raw ASCNs we relabel A1, A2,..., Am and B1, B2,...,
Bm. Our inferred minor chromosome PSCN is then
T 3
Pm
j¼1 minimumðAj;BjÞ
Pm
j¼1 ðAj þ BjÞ
ð4Þ
rounded to the nearest integer. In order to ensure that total copy
number is T, the inferred major chromosome PSCN is T   (inferred
minor chromosome PSCN).
Once PSCNs are determined, the ASCNs follow immediately from
these and the raw ASCNs. The homozygous SNPs (determined as in
the paragraph above) are assigned the allele with the larger raw
ASCN. Heterozygous SNPs are assigned ASCNs so that the allele with
the larger raw ASCN has the copy number of the major parental
chromosome.
PCR-based copy number validation. Relative copy numbers for
both alleles of a SNP site were determined by quantitative real-time
PCR using both a PRISM 7500 Sequence Detection System (96 well)
and a PRISM 7900HT Sequence Detection System (384 well)
(Applied Biosystems, Foster City, California, United States). Real-
time PCR was performed in 25-ll (96 well) or 12.5-ll (384 well)
reactions with 2 ng or 1 ng, respectively, of template DNA. SYBR
Green I (Molecular Probes; Eugene, Oregon, United States) and the
Stoffel fragment of Taq polymerase (Applied Biosystems) [27] were
used for the PCR reaction. The reaction mix used was as described
previously [27], with the following exceptions: 3U of Stoffel
polymerase, 100 lM dUTP, and 0.5 lM ROX (Invitrogen, Carlsbad,
California, United States) were used per reaction. Primers were
designed with the help of Primer 3 (http://frodo.wi.mit.edu/cgi-bin/
primer3/primer3_www.cgi) and synthesized by Invitrogen. For each
SNP site three primers were designed, one common for the region
and two designed with the 39 base of the primer speciﬁc for each
SNP allele. The common primer plus one of the SNP-speciﬁc
primers were used for each PCR reaction (0.3 lM each). Primer
sequences are available upon request. PCR conditions were as
follows: 2 min at 50 8C, 15 min at 95 8C, followed by 47 three-step
cycles of (20 s at 95 8C, 20 s at 60 8C, and 30 s at 72 8C). The
standard curve method was used to calculate the copy number of
each allele of a target SNP site in the tumor DNA sample relative to
a reference, the Line-1 repetitive element whose copy number is
similar between both normal and cancerous cells. Quantiﬁcation
was based on standard curves from a serial dilution of human
normal genomic DNA. The relative target copy number level for
each allele of a SNP target site was normalized to normal human
genomic DNA, heterozygous for that particular SNP site, as
calibrator. Changes in the target allele copy number relative to
the Line-1 and the calibrator were determined using the formula
(Ttarget/TLine-1)/(Ctarget/CLine-1), where Ttarget and TLine-1 are the DNA
quantities from tumor by using the target allele and Line-1, and
Ctarget and CLine-1 are the DNA quantities from the calibrator by
using the target allele and Line-1. The copy number of both alleles
for each SNP site was determined in this way.
Real-time PCR was also used to determine the relative copy
number of the two EGFR alleles in the HCC827 cell line, which
contains the E746 A750del mutation and an ampliﬁcation of the
EGFR region. Real-time PCR was performed with the Stoffel fragment
of Taq polymerase using reaction mix and conditions described
above. The standard curve method was used to calculate the total
copy number of the EGFR gene and the copy number of the wild-type
allele in the HCC827 DNA sample normalized to Line-1 and a normal
reference DNA. The primer pairs consisted of one common reverse
primer, with one forward primer that would bind both EGFR alleles
(wild-type and mutated) and one forward primer speciﬁc for the wild-
type allele. The primer speciﬁc for the wild-type EGFR allele was
designed so that the 39 end was located within the DNA deleted by the
E746 A750del mutation. Two PCR reactions were performed: one
that gave total EGFR copy number (using primer that binds both
alleles) and one that gave only wild-type EGFR copy number (using
primer speciﬁc for wild-type EGFR).
Supporting Information
Accession Numbers
The NCBI Entrez Gene (http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?db¼gene) accession numbers for the genes discussed in this
paper are cyclin D1 (595), EGFR (1956), HRAS (3265), and MET (4233).
Figure 5. The PLASQ Procedure for Determining ASCN and PSCN from
the .cel Files
After normalizing signal intensities from all samples, the model is first fit
to the normal samples’ data to produce both genotype calls and
parameter estimates at each SNP site. The latter are used in the model as
applied to the data from the cancer samples. Ordinary least squares
fitting produces raw ASCN estimates at each SNP. The corresponding raw
total copy number estimates are smoothed using circular binary
segmentation. Finally, further processing yields our final ASCN and
PSCN inferences (see Materials and Methods). EM algorithm, expectation-
maximization algorithm.
DOI: 10.1371/journal.pcbi.0010065.g005
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